Drug Trial Radar · NCT00447759
The Standard Care Versus Celecoxib Outcome Trial
Last checked: Nov 19, 2026Latest source record: May 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,297
Actual
Start
Jun 2007
Primary completion
Aug 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- University of DundeeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Glasgow; University of Nottingham
- First posted
- Mar 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Standard Care versus Celecoxib Outcome Trial (SCOT) is a large streamline safety study designed to compare the cardiovascular safety of celecoxib versus traditional non-selective Non Steroidal Anti-Inflammatory Drug (NSAID) therapy.Traditional NSAID's are associated with significant morbidity and mortality from gastrointestinal toxicity. Cyclooxygenase 2 (Cox-2)selective agents are associated with reduced upper gastrointestinal toxicity.Traditional NSAID's and Cox-2 inhibitors may also be associated with cardiovascular and renal disorders. Data from both randomised and observational studies suggest that celecoxib has similar or reduced cardiovascular toxicity when compared to traditional NSAID's. However, the overall safety balance of a strategy of celecoxib therapy versus a strategy of NSAID therapy is unknown. The European Medicines Evaluation Agency (EMEA) has requested that studies of the cardiovascular safety of celecoxib be carried out within the indicated population of Europe. This study addresses these issues by comparing the cardiovascular safety of celecoxib therapy with traditional NSAID therapy in the setting of the EU healthcare system. As of May 2013, 7300 patients had been randomised, and had accrued an average 4.2 years of follow up by the end of May 2014.
Conditions
- Osteoarthritis
- Rheumatoid Arthritis
Interventions
CelecoxibDrug
200-400mg daily in divided doses
DiclofenacDrug
prescribed medication taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- compare cardiovascular safety of celecoxib and traditional NSAIDs prescribed for the treatment of arthritis.Time frame: 4 years
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
University of Southern Denmark
Odense, Denmark
Julius Clinical Research
Zeist, Netherlands
University of Aberdeen
Aberdeen, United Kingdom
University of Birmingham
Birmingham, United Kingdom
University of Dundee
Dundee, United Kingdom
University of Edinburgh
Edinburgh, United Kingdom
University of Glasgow
Glasgow, United Kingdom
NHS Highlands
Inverness, United Kingdom
University of Nottingham
Nottingham, United Kingdom
University of Oxford
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.